AgNOR histochemical expression in benign prostatic hyperplasia and prostatic adenocarcinoma

Benign prostatic hyperplasia and prostatic adenocarcinoma were common diseases and usually occurred after the 5th decade of life. The problem in diagnosing using Hematoxylin and Eosin staining was how to differentiate whether it is benign or malignant zone. Therefore, proliferating markers, such as...

Full description

Saved in:
Bibliographic Details
Published in:IOP conference series. Earth and environmental science 2018-03, Vol.125 (1), p.12220
Main Authors: Rita, R, Delyuzar, Laksmi, L I
Format: Article
Language:English
Subjects:
Adenocarcinoma
Benign
Cancer
Hyperplasia
Staining
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Benign prostatic hyperplasia and prostatic adenocarcinoma were common diseases and usually occurred after the 5th decade of life. The problem in diagnosing using Hematoxylin and Eosin staining was how to differentiate whether it is benign or malignant zone. Therefore, proliferating markers, such as AgNOR, could be helping to over this difficulty. A descriptive study using consecutive sampling as the method of sample recruiting was conducted to describe AgNOR histochemical expression in benign prostatic hyperplasia and prostatic adenocarcinoma. AgNOR staining was done in 13 benign prostatic hyperplasia samples and 7 prostatic adenocarcinoma samples, which have been confirmed using p63 immunohistochemical staining before. Benign prostatic hyperplasia usually showed lower AgNOR proliferating activity while all of theprostatic adenocarcinoma (100%) had high AgNOR proliferating activity.
ISSN:1755-1307
1755-1315
DOI:10.1088/1755-1315/125/1/012220